efatutazone for Liposarcoma

"Our team at Power assigned efatutazone a score of 2, due to the Phase 2 trial status that implies some evidence for safety but no research on efficacy."

"Currently, two studies are underway investigating efatutazone. Neither of these trials is in their final stage yet. While the main site for research on this medication is located in Peoria, Illinois, 380 other locations have also launched clinical trials with efatutazone as a potential treatment option."

"As reported via clinicaltrials.gov, this medical trial has concluded its recruitment process and is no longer actively seeking participants. Initially posted on October 1st 2014, the last update occurred on August 16th 2021. However, there are still 46 other trials currently enrolling patients for evaluation."

"Since 2014, Daiichi Sankyo has sponsored research into efatutazone. This began with a Phase 1 trial involving 19 patients and culminated in the drug being approved for use during its second stage of testing. Currently, two active studies are running across 224 cities and one nation."

"Unfortunately, the recruitment period for this clinical trial has lapsed. It was first posted on October 1st 2014 and last edited August 16th 2021. For individuals who are still seeking a medical study to join, there are currently 44 trials that require patients with liposarcoma and 2 studies involving efatutazone actively recruiting participants."

"This extensive research project is currently taking place in over a hundred locations, with notable sites located in Maywood, Oklahoma City and Mattoon. To minimize the need to travel if you join the study it is best to choose an available site near your home location."